|
| |
Taiho Pharmaceutical TS-1 Pages on BioPortfolio:
BioPortfolio Taiho Pharmaceutical TS1
Taiho Pharmaceuticals TS1tegafur gimeracil & oteracil 66 Taiho Pharmaceuticals UFTtegafur & uracil 67 Pharmion Corp's Vidaza5azacitidine 68 ...
http://www.bioportfolio.com/search/Taiho_Pharmaceutical_TS-1...
|
BioPortfolio - Taiho Pharmaceutical Company Limited
As a measure to ensure safe use of TS-1 during the early marketing period,... 4th February, 2006, Taiho Pharmaceutical Company, Tokyo, Japan. ...
http://www.bioportfolio.com/biocorporate/9990-Taiho_Pharmace...
|
BioPortfolio Taiho Pharmaceutical Company Limited
As a measure to ensure safe use of TS1 during the early marketing period, 4th February 2006, Taiho Pharmaceutical Company Tokyo Japan, Gan To Kagaku Ryoho ...
http://www.bioportfolio.com/biocorporate/9990-Taiho%252BPhar...
|
BioPortfolio taiho pharma uk general manager
Recent Search Terms used to find this page Taiho Pharmaceutical | taiho pharmaceutical | taiho pharma uk general manager | Taiho Pharmaceutical TS1 ...
http://www.bioportfolio.com/search/taiho_pharma_uk_general_m...
|
BioPortfolio DLST research
A case of druginduced interstitial pneumonia caused by TS1, 15th May 2008 ... Drug Safety Lab Taiho Pharmaceutical Co Ltd ...
http://www.bioportfolio.com/gene/1743-DLST/research.html...
|
BioPortfolio Limited Top 20 Cancer Therapy Brands Sales of ...
TS1Tegafur gimeracil & oteracil Taiho PharmaceuticalsSanofiAventis 115 UFTTegafur & uracil Taiho Pharmaceuticals 117 XelodaCapecitabine Roche ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_780.html...
|
Commercial Insight Top 20 Cancer Therapeutics
Taiho Pharmaceuticals' TS-1 (tegafur, gimeracil & oteracil) 66 Taiho Pharmaceuticals' UFT (tegafur & uracil) 67 Pharmion Corp's Vidaza (5-azacitidine) 68 ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_503.html...
|
Search BioPortfolio BioPortfolio Web Home Careers Conferences ...
Tokyo Japan Jul 10 2006JCN Newswire via COMTEXTaiho Pharmaceutical and sanofiaventis have entered into a licensing agreement for TS1 an anticancer agent ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...
|
Search BioPortfolio: BioPortfolio Web Home Careers Conferences ...
Taiho Pharmaceutical, Sanofi-aventis Conclude Licensing Agreement for Oral Pyrimidine Fluoride-derived Anticancer Agent TS-1 ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...
|
Results from other life science and pharmaceutical sites:
BioPortfolio - Taiho Pharmaceutical Company Limited
As a measure to ensure safe use of TS-1 during the early marketing period,... 4th February, 2006, Taiho Pharmaceutical Company, Tokyo, Japan. ...
http://www.bioportfolio.com/biocorporate/9990-Taiho_Pharmace...
|
[DLST as a method for detecting TS-1-induced aller...[Gan To ...
Drug Safety Lab., Taiho Pharmaceutical Co., Ltd. ... In this case report, we conducted the DLST on 20 healthy volunteers without TS-1 treatment in order to ...
http://www.ncbi.nlm.nih.gov/pubmed/16531715...
|
BioSpace - Taiho Pharmaceutical News, Search Jobs, Events
Taiho Pharmaceutical And Sanofi-Aventis (France) (SASY.PA) Conclude Licensing Agreement For Oral Pyrimidine Fluoride-Derived Anticancer Agent TS-1 7/10/2006 ...
http://www.biospace.com/company_profile.aspx?CompanyId=2746...
|
[Benefits of TS-1 plus leucovorin combination ther...[Gan To ...
Optimal Medication Research Laboratory, Taiho Pharmaceutical Co., Ltd. We evaluated the therapeutic effect of TS-1, a novel oral fluoropyrimidine, ...
http://www.ncbi.nlm.nih.gov/pubmed/17353633...
|
Patent News
Taiho Pharmaceutical Co Ltd and its parent company. Otsuka Pharmaceutical Co Ltd have requested ... extensions on JP-02614164 and JP-02538422 for the TS-1 ...
http://www.biomedcentral.com/content/pdf/cd-665393.pdf...
|
[New oral anticancer drug, TS-1 (S-1)--from bench ...[Gan To ...
[New oral anticancer drug, TS-1 (S-1)--from bench to clinic] ... Laboratory, Pathogenic Biochemistry in Medicine, Taiho Pharmaceutical Co., Ltd. ...
http://www.ncbi.nlm.nih.gov/pubmed/11432358...
|
Thymidylate Synthase, Thymidine Phosphorylase and Orotate ...
TS-1 (Taiho Pharmaceutical Co, Ltd. Tokyo Japan) was given for 14 days as neoadjuvant chemotherapy [17]. The dosage of TS-1 was selected as follows: in a ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=24...
|
[Example of safety measures for antineoplastic age...[Gan To ...
Taiho Pharmaceutical Company, Tokyo, Japan. As a measure to ensure safe use of TS-1 during the early marketing period, a drug use investigation was ...
http://www.ncbi.nlm.nih.gov/pubmed/16410699...
|
cd-910492 Patent news Patent news Thomson Current Awareness ...
Further patent extensions reported for Taiho combination product in Japan Taiho Pharmaceutical Co Ltd and Otsuka Pharmaceutical Co Ltd have received three ...
http://www.biomedcentral.com/content/download/xml/cd-910492....
|
Clinical Pharmacology & Therapeutics - The CYP2A6[ast]4 Allele Is ...
S-1 (TS-1; Taiho Pharmaceutical, Tokyo, Japan) is a new oral anticancer agent classified as a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine. ...
http://www.nature.com/clpt/journal/v83/n4/full/6100484a.html...
|
|
